{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:28:00Z","timestamp":1762543680611,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:00:00Z","timestamp":1698537600000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ygyno.2022.09.013","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T21:21:30Z","timestamp":1663708890000},"page":"323-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma"],"prefix":"10.1016","volume":"167","author":[{"given":"Amnon A.","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A.","family":"Kawaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"Misirlioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto Arostegui","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narciso","family":"Olvera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Van Oudenhove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"DeLair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.09.013_bb0005","first-page":"1","article-title":"Trends of uterine carcinosarcoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0010","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2018.811","article-title":"Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus","volume":"12","author":"Berger","year":"2018","journal-title":"Ecancermedicalscience."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021, CA","volume":"71","author":"Siegel","year":"2021","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020, CA","volume":"70","author":"Siegel","year":"2020","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Getz","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0030","first-page":"325","article-title":"Regulation of VEGF in the reproductive tract by sex-steroid hormones","volume":"15","author":"Hyder","year":"2000","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11912-014-0403-3","article-title":"Current status of molecular biomarkers in endometrial cancer","volume":"16","author":"Werner","year":"2014","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0040","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ygyno.2020.12.016","article-title":"Angiogenesis in endometrial carcinoma: therapies and biomarkers, current options, and future perspectives","volume":"160","author":"Berger","year":"2021","journal-title":"Gynecol. Oncol."},{"year":"2006","series-title":"Angiogenesis and the Inception of Pregnancy","author":"Kapiteijn","key":"10.1016\/j.ygyno.2022.09.013_bb0045"},{"key":"10.1016\/j.ygyno.2022.09.013_bb0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-540-73259-4_6","article-title":"Therapeutic anti-VEGF antibodies","volume":"181","author":"Lien","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0055","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","article-title":"A phase II study of frontline paclitaxel\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or ixabepilone\/carboplatin\/bevacizumab in advanced\/recurrent endometrial cancer","volume":"150","author":"Aghajanian","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0065","first-page":"886","article-title":"Tissue factor induces VEGF expression via activation of the Wnt\/\u03b2-catenin signaling pathway in ARPE-19 cells","volume":"22","author":"Wang","year":"2016","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0070","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/emboj\/16.13.3797","article-title":"\u0392-catenin is a target for the ubiquitin-proteasome pathway","volume":"16","author":"Aberle","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0075","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.18632\/oncotarget.23695","article-title":"Exon 3 mutations of CTNNB1 drive tumorigenesis: a review","volume":"9","author":"Gao","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0080","first-page":"131","article-title":"The role of Wnt signalling in angiogenesis","volume":"38","author":"Olsen","year":"2017","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ygyno.2017.02.031","article-title":"FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"145","author":"Jeske","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0090","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0095","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","article-title":"Proteogenomic characterization of endometrial carcinoma","volume":"180","author":"Dou","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0100","series-title":"Wnt Target genes | The Wnt Homepage","first-page":"8","author":"Nusse","year":"2012"},{"key":"10.1016\/j.ygyno.2022.09.013_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0110","doi-asserted-by":"crossref","first-page":"14771","DOI":"10.1073\/pnas.0706578104","article-title":"Distinct pathways of genomic progression to benign and malignant tumors of the liver","volume":"104","author":"Tward","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaa1877","article-title":"Systematic identification of signaling pathways with potential to confer anticancer drug resistance","volume":"7","author":"Martz","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0120","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/1541-7786.MCR-10-0223","article-title":"A coactivator role of CARM1 in the dysregulation of \u03b2-catenin activity in colorectal cancer cell growth and gene expression","volume":"9","author":"Ou","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0125","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2019.10.013","article-title":"Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial","volume":"155","author":"Lorusso","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0135","first-page":"8","article-title":"Mutation hotspots in the \u03b2-catenin gene: lessons from the human cancer genome databases","volume":"42","author":"Kim","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2022.09.013_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2013.11.002","article-title":"Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning","volume":"25","author":"Vempati","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0145","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2008-08-172742","article-title":"Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells","volume":"113","author":"Ito","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0155","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1073\/pnas.1902145116","article-title":"Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy","volume":"117","author":"Kashyap","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2022.09.013_bb0160","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:03:37Z","timestamp":1758773017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822018273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0090825822018273"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.09.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}